Cascade N-Acyliminium Ion/aza-Prins Cyclization

Electronic Supporting Information for

ESI

Acetic Acid-Promoted Cascade *N*-Acyliminium ion/*aza*-Prins Cyclization: Stereoselective Synthesis of Functionalized Fused Tricyclic Piperidines

Rajiv T. Sawant^a, Marc Y. Stevens^a and Luke R. Odell*^a

^{*a*}Organic Pharmaceutical Chemistry, Department of Medicinal Chemistry, Uppsala Biomedical Center, Uppsala University, P.O. Box 574, SE-751 23 Uppsala, Sweden

Contents

General Information
General procedure for cascade aza-Prins cyclisation, exemplified by the preparation of (\pm) -6-Oxo-5,8,9,10,11,11a-hexahydro-6 <i>H</i> -pyrido[1,2- <i>c</i>]quinazolin-10-yl acetate (3a)4
$ (\pm) \text{-} 6 \text{-} Oxo \text{-} 5, 8, 9, 10, 11, 11a \text{-} hexahydro \text{-} 6 \text{H-} pyrido [1, 2-c] quinazolin \text{-} 10 \text{-} yl) formate (3b) \dots 5 \\ $
(±)-6-Oxo-5,8,9,10,11,11a-hexahydro-6H-pyrido[1,2-c]quinazolin-10-yl propionate (3c)5
(±)-2-Methoxy-6-oxo-5,8,9,10,11,11a-hexahydro-6 <i>H</i> -pyrido[1,2- <i>c</i>]quinazolin-10-yl acetate (4)
(±)-2-Bromo-6-oxo-5,8,9,10,11,11a-hexahydro-6 <i>H</i> -pyrido[1,2- <i>c</i>]quinazolin-10-yl acetate (5)7
(±)-2-Fluoro-6-oxo-5,8,9,10,11,11a-hexahydro-6 <i>H</i> -pyrido[1,2- <i>c</i>]quinazolin-10-yl acetate (6) 7
(±)-3-Chloro-6-oxo-5,8,9,10,11,11a-hexahydro-6 <i>H</i> -pyrido[1,2- <i>c</i>]quinazolin-10-yl acetate (7)8
(±)-6-Oxo-3-(trifluoromethyl)-5,8,9,10,11,11a-hexahydro-6 <i>H</i> -pyrido[1,2- <i>c</i>]quinazolin-10-yl acetate (8)
(±)-4-Methoxy-6-oxo-5,8,9,10,11,11a-hexahydro-6 <i>H</i> -pyrido[1,2- <i>c</i>]quinazolin-10-yl acetate (9)
(±)-4-Methyl-6-oxo-5,8,9,10,11,11a-hexahydro-6 <i>H</i> -pyrido[1,2- <i>c</i>]quinazolin-10-yl acetate (10)
(±)-6-Oxo-5,8,9,10,11,11a-hexahydro-6 <i>H</i> -dipyrido[1,2- <i>c</i> :3',2'- <i>e</i>]pyrimidin-10-yl acetate (11)
(\pm) -5-Methyl-6-oxo-5,8,9,10,11,11a-hexahydro-6 <i>H</i> -pyrido[1,2- <i>c</i>]quinazolin-10-yl acetate (12)
(±)-5-Allyl-6-oxo-5,8,9,10,11,11a-hexahydro-6 H -pyrido[1,2- c]quinazolin-10-yl acetate (13)
(±)-5-Benzyl-6-oxo-5,8,9,10,11,11a-hexahydro-6 <i>H</i> -pyrido[1,2- <i>c</i>]quinazolin-10-yl acetate (14)
(±)-Ethyl-2-(10-acetoxy-6-oxo-9,10,11,11a-tetrahydro-6 <i>H</i> -pyrido[1,2- <i>c</i>]quinazolin-5(8 <i>H</i>)- yl)acetate (15)
(±)-6-Oxo-8-phenyl-5,8,9,10,11,11a-hexahydro-6 <i>H</i> -pyrido[1,2- <i>c</i>]quinazolin-10-yl acetate (16)
(±)-10-Hydroxy-5,8,9,10,11,11a-hexahydro-6 <i>H</i> -pyrido[1,2- <i>c</i>]quinazolin-6-one (17)15
(±)15
(\pm) -8,9,11,11a-Tetrahydro-6 <i>H</i> -pyrido[1,2- <i>c</i>]quinazoline-6,10(5 <i>H</i>)-dione (18)15
(±)-5-Ethyl-6-oxo-5,8,9,10,11,11a-hexahydro-6 <i>H</i> -pyrido[1,2- <i>c</i>]quinazolin-10-yl acetate (19)
NOE experiments for the determination of relative stereochemistry of compounds 3a, 10 and
16

Literature references	17
¹ H and ¹³ C NMR spectra	19

General Information

All reagents were purchased at the highest commercial quality and used without further purification. Yields refer to isolated, homogenous and spectroscopically pure material, unless otherwise stated. Crude reaction mixtures were purified by silica gel chromatography (E. Merck silica gel, particle size 0.043–0.063 mm) and thin layer chromatography was carried out using E. Merck silica plates (60F-254) with UV light (254 nm) as the visualization agent. Microwave reactions were carried out in an Initiator single-mode reactor producing controlled radiation at 2450 MHz, and temperature was monitored via the built-in online IR sensor. ¹H NMR spectra were recorded at 400 MHz and ¹³C{¹H} NMR spectra at 100 MHz. The chemical shifts for ¹H NMR and ¹³C{¹H} NMR spectra were referenced to tetramethylsilane *via* residual solvent signals (¹H, CDCl₃ at 7.26 ppm, CD₃OD at 3.31 ppm; ¹³C, CDCl₃ at 77.16 ppm, CD₃OD at 49.0 ppm). LC/MS was performed on an instrument equipped with a C18 column (50 × 3.0 mm, particle size 2.6 μ m, pore size 100 Å). Accurate mass values were determined using a mass spectrometer equipped with an electrospray ion source and time-of-flight detector. Electrophilic precursors **1a–1m** were prepared following the literature procedure.^[1,2]

General procedure for cascade aza-Prins cyclisation, exemplified by the preparation of (\pm) -6-Oxo-5,8,9,10,11,11a-hexahydro-6*H*-pyrido[1,2*c*]quinazolin-10-yl acetate (3a)



Exact Mass: 260.1161

A sealed 0.5–2 mL Pyrex process vial charged with aldehyde **1a** (40 mg, 223 μ mol), amine **2a** (20 mg, 281 μ mol) and acetic acid (1 mL) was subjected to microwave irradiation at 140 °C for 20 min. The reaction mixture was cooled to room temperature, diluted with 2 mL ethyl acetate. The volatiles were concentrated in vacuo and the residue was purified by silica gel chromatography (55% EtOAc in *n*-pentane) to yield the title compound as a white solid (49 mg, 189 μ mol, 86%, 99/1 *cis/trans* ratio).

¹H NMR (400 MHz; CDCl₃) δ 1.58–1.69 (m, 1H), 1.99–2.03 (m, 1H), 2.04 (s, 4H), 2.27 (ddt, J = 12.4, 4.6, 2.3, 2.3 Hz, 1H), 2.73 (ddd, J = 13.8, 12.9, 2.6 Hz, 1H), 4.55 (dd, J = 12.0, 2.6 Hz, 1H), 4.69 (ddd, J = 13.8, 4.6, 2.4 Hz, 1H), 4.90–5.26 (m, 1H), 6.61–6.76 (m, 1H), 6.91–6.98 (m, 1H), 7.00–7.07 (m, 1H), 7.11–7.20 (m, 1H), 7.88 (s, 1H).

¹³C NMR (100 MHz; CDCl₃) δ 21.4, 30.6, 39.7, 41.8, 56.6, 71.1, 114.0, 120.0, 122.3, 125.6, 128.7, 135.7, 152.8, 170.5.

HRMS (ESI) calc'd for C₁₆H₂₀N₃O₃ m/z 302.1505, found m/z 302.1508 (MeCN + H⁺ adduct).

(±)-6-Oxo-5,8,9,10,11,11a-hexahydro-6H-pyrido[1,2-c]quinazolin-10-yl)formate (3b)



Chemical Formula: C₁₃H₁₄N₂O₃ Exact Mass: 246.1004

Prepared following the general procedure, using formic acid (1 mL) instead of AcOH. Starting from aldehyde **1a** (40 mg, 223 μ mol) and amine **2a** (20 mg, 281 μ mol), the title compound was obtained after silica gel chromatography (55% EtOAc in *n*-pentane) as a white solid (20 mg, 83 μ mol, 36%, 99/1 *cis/trans* ratio).

¹H NMR (400 MHz; CDCl₃) δ 1.63–1.74 (m, 1H), 2.00 – 2.10 (m, 1H), 2.21–2.35 (m, 1H), 2.74 (td, *J* = 13.4, 13.4, 2.6 Hz, 1H), 4.56 (dd, *J* = 11.9, 2.6 Hz, 1H), 4.72 (ddd, *J* = 13.9, 4.7, 2.4 Hz, 1H), 5.12–5.22 (m, 1H), 6.72 (dd, *J* = 8.0, 1.1 Hz, 1H), 6.88–7.00 (m, 1H), 7.00–7.07 (m, 1H), 7.11–7.23 (m, 1H), 8.03 (s, 1H), 8.27 (s, 1H).

¹³C NMR (100 MHz; CDCl₃) δ 30.5, 39.5, 41.7, 56.5, 70.9, 114.2, 119.7, 122.3, 125.5, 128.8, 135.8, 153.0, 160.4.

HRMS (ESI) calc'd for $C_{13}H_{15}N_2O_3 m/z$ 247.1083, found m/z 247.1092.

(±)-6-Oxo-5,8,9,10,11,11a-hexahydro-6H-pyrido[1,2-c]quinazolin-10-yl propionate (3c)



Chemical Formula: C₁₅H₁₈N₂O₃ Exact Mass: 274.1317

Prepared following the general procedure, using propionic acid (1 mL) instead of AcOH. Starting from aldehyde **1a** (40 mg, 223 μ mol) and amine **2a** (21 mg, 295 μ mol), the title compound was obtained after silica gel chromatography (30–55% EtOAc in *n*-pentane) as a white solid (31 mg, 113 μ mol, 51%, 97/3 *cis/trans* ratio).

¹H NMR (400 MHz; CDCl₃) δ 1.12 (t, *J* = 7.6, 7.6 Hz, 3H), 1.55–1.67 (m, 1H), 1.67–1.75 (m, 1H), 1.97–2.07 (m, 1H), 2.23–2.29 (m, 2H), 2.29–2.34 (m, 1H), 2.64–2.80 (m, 1H), 4.54 (dd, *J* = 12.0, 2.6 Hz, 1H), 4.69 (ddd, *J* = 13.8, 4.7, 2.4 Hz, 1H), 5.03 (ddd, *J* = 11.3, 6.7, 4.6 Hz, 1H), 6.70–6.77 (m, 1H), 6.89–6.95 (m, 1H), 6.99–7.04 (m, 1H), 7.13–7.19 (m, 1H), 8.71 (s, 1H).

¹³C NMR (100 MHz; CDCl₃) δ 27.8, 30.5, 39.6, 41.6, 56.4, 70.7, 114.0, 119.8, 122.0, 125.3, 128.5, 135.8, 153.1, 173.8.

HRMS (ESI) calc'd for $C_{17}H_{22}N_3O_3 m/z$ 316.1661, found m/z 316.1675 (MeCN + H⁺ adduct).

(±)-2-Methoxy-6-oxo-5,8,9,10,11,11a-hexahydro-6*H*-pyrido[1,2*c*]quinazolin-10-yl acetate (4)



Chemical Formula: C₁₅H₁₈N₂O₄ Exact Mass: 290.1267

Prepared following the general procedure, starting from aldehyde **1b** (40 mg, 191 μ mol) and amine **2a** (21 mg, 295 μ mol), the title compound was obtained after silica gel chromatography (70% EtOAc in *n*-pentane) as a white solid (48 mg, 164 μ mol, 86%, 96/4 *cis/trans* ratio).

¹H NMR (400 MHz; CDCl₃) δ 1.59–1.76 (m, 2H), 1.97–2.04 (m, 1H), 2.04 (s, 3H), 2.23–2.34 (m, 1H), 2.71 (ddd, J = 13.8, 12.9, 2.6 Hz, 1H), 3.75 (s, 3H), 4.50 (dd, J = 12.0, 2.5 Hz, 1H), 4.68 (ddd, J = 13.8, 4.6, 2.4 Hz, 1H), 5.01 (tt, J = 11.3, 11.3, 4.6, 4.6 Hz, 1H), 6.58 (d, J = 2.7 Hz, 1H), 6.63 (d, J = 8.6 Hz, 1H), 6.73 (dd, J = 8.6, 2.7 Hz, 1H), 7.80 (s, 1H).

¹³C NMR (100 MHz; CDCl₃) δ 21.4, 30.5, 39.4, 41.8, 55.8, 56.8, 71.1, 110.9, 114.4, 115.0, 120.9, 129.3, 152.9, 155.2, 170.5.

HRMS (ESI) calc'd for $C_{15}H_{19}N_2O_4 m/z$ 291.1345, found m/z 291.1343.

(±)-2-Bromo-6-oxo-5,8,9,10,11,11a-hexahydro-6*H*-pyrido[1,2-*c*]quinazolin-10-yl acetate (5)



Chemical Formula: C₁₄H₁₅BrN₂O₃ Exact Mass: 338.0266

Prepared following the general procedure, starting from aldehyde 1c (40 mg, 155 μ mol) and amine 2a (21 mg, 295 μ mol), the title compound was obtained after silica gel chromatography (45% EtOAc in *n*-pentane) as a white solid (45 mg, 132 μ mol, 85%, 95/5 *cis/trans* ratio).

¹H NMR (400 MHz; CDCl₃) δ 1.56–1.78 (m, 2H), 2.05 (s, 3H), 2.27 (ddt, *J* = 12.3, 4.6, 2.3, 2.3 Hz, 1H), 2.72 (ddd, *J* = 13.8, 13.0, 2.6 Hz, 1H), 4.52 (dd, *J* = 12.3, 2.6 Hz, 1H), 4.67 (ddd, *J* = 13.8, 4.6, 2.4 Hz, 1H), 5.00 (tt, *J* = 11.3, 11.3, 4.6, 4.6 Hz, 1H), 6.61 (d, *J* = 8.5 Hz, 1H), 7.16 (d, *J* = 2.1 Hz, 1H), 7.24–7.28 (m, 1H), 8.33 (s, 1H).

¹³C NMR (100 MHz; CDCl₃) δ 21.3, 30.5, 39.6, 41.8, 56.1, 70.8, 114.3, 115.7, 121.9, 128.5, 131.6, 135.0, 152.6, 170.5.

HRMS (ESI) calc'd for C₁₆H₁₉BrN₃O₃ m/z 380.0160, found m/z 380.0628 (MeCN + H⁺) adduct.

(±)-2-Fluoro-6-oxo-5,8,9,10,11,11a-hexahydro-6*H*-pyrido[1,2-*c*]quinazolin-10-yl acetate (6)



Chemical Formula: C₁₄H₁₅FN₂O₃ Exact Mass: 278.1067

Prepared following the general procedure, starting from aldehyde **1d** (40 mg, 203 μ mol) and amine **2a** (21 mg, 295 μ mol), the title compound was obtained after silica gel chromatography (53% EtOAc in *n*-pentane) as a white solid (46 mg, 165 μ mol, 81%, 96/4 *cis/trans* ratio).

¹H NMR (400 MHz; CDCl₃) δ 1.57–1.78 (m, 2H), 2.00–2.04 (m, 1H), 2.05 (s, 3H), 2.26 (ddt, J = 12.4, 4.6, 2.3, 2.3 Hz, 1H), 2.72 (ddd, J = 13.8, 12.9, 2.6 Hz, 1H), 4.52 (dd, J = 11.9, 2.6

Hz, 1H), 4.68 (ddd, *J* = 13.9, 4.6, 2.4 Hz, 1H), 4.85–5.21 (m, 1H), 6.67 (dd, *J* = 8.7, 4.6 Hz, 1H), 6.76 (dd, *J* = 8.7, 2.8 Hz, 1H), 6.83–6.98 (m, 1H), 8.31 (s, 1H).

¹³C NMR (100 MHz; CDCl₃) δ 21.7, 30.8, 39.7, 42.1, 56.7 (d, ⁴*J*_{CF} = 1.9 Hz), 71.2, 112.7 (d, ²*J*_{CF} = 24.0 Hz), 115.57 (d, ³*J*_{CF} = 7.8 Hz), 115.87 (d, ²*J*_{CF} = 22.9 Hz), 121.6 (d, ³*J*_{CF} = 7.3 Hz), 132.4 (d, ⁴*J*_{CF} = 2.3 Hz), 153.2, 158.6 (d, ¹*J*_{CF} = 240.7 Hz), 170.8.

HRMS (ESI) calc'd for $C_{16}H_{19}FN_3O_3 m/z$ 320.1410, found m/z 320.1414 (MeCN + H⁺ adduct).

(±)-3-Chloro-6-oxo-5,8,9,10,11,11a-hexahydro-6*H*-pyrido[1,2-*c*]quinazolin-10-yl acetate (7)



Chemical Formula: C₁₄H₁₅ClN₂O₃ Exact Mass: 294.0771

Prepared following the general procedure, starting from aldehyde **1e** (40 mg, 203 μ mol) and amine **2a** (21 mg, 295 μ mol), the title compound was obtained after silica gel chromatography (45% EtOAc in *n*-pentane) as a white solid (45 mg, 155 μ mol, 83%, 94/6 *cis/trans* ratio).

¹H NMR (400 MHz; CDCl₃) δ 1.56–1.78 (m, 3H), 2.05 (s, 3H), 2.21–2.31 (m, 1H), 2.68–2.80 (m, 1H), 4.52 (dd, J = 11.9, 2.6 Hz, 1H), 4.69 (ddd, J = 13.7, 4.7, 2.4 Hz, 1H), 4.96–5.06 (m, 1H), 6.73 (d, J = 1.9 Hz, 1H), 6.90 (dd, J = 8.2, 1.9 Hz, 1H), 6.95 (d, J = 8.2 Hz, 1H), 8.36 (s, 1H).

¹³C NMR (100 MHz; CDCl₃) δ 21.2, 30.4, 39.5, 41.7, 56.0, 70.7, 113.8, 118.3, 122.2, 126.6, 134.1, 136.8, 152.3, 170.3.

HRMS (ESI) calc'd for $C_{16}H_{19}ClN_3O_3 m/z$ 336.1115, found m/z 336.1128 (MeCN + H⁺ adduct).

(±)-6-Oxo-3-(trifluoromethyl)-5,8,9,10,11,11a-hexahydro-6*H*-pyrido[1,2-c]quinazolin-10-yl acetate (8)



Chemical Formula: C₁₅H₁₅F₃N₂O₃ Exact Mass: 328.1035

Prepared following the general procedure, starting from aldehyde **1f** (40 mg, 161 μ mol) and amine **2a** (21 mg, 295 μ mol), the title compound was obtained after silica gel chromatography (45% EtOAc in *n*-pentane) as a white solid (45 mg, 136 μ mol, 84%, 93/7 *cis/trans* ratio).

¹H NMR (400 MHz; CDCl₃) δ 1.61–1.80 (m, 3H), 2.05 (s, 3H), 2.25–2.35 (m, 1H), 2.68–2.84 (m, 1H), 4.60 (dd, J = 12.1, 2.5 Hz, 1H), 4.71 (ddd, J = 13.9, 4.6, 2.4 Hz, 1H), 5.04 (tt, J = 11.3, 11.3, 4.6, 4.6 Hz, 1H), 6.95–6.98 (m, 1H), 7.12–7.16 (m, 1H), 7.17–7.21 (m, 1H), 8.75 (s, 1H).

¹³C NMR (100 MHz; CDCl₃) δ 21.3, 30.5, 39.5, 41.9, 56.4, 70.8, 111.0 (q, ³*J*_{CF} = 3.7 Hz), 118.9 (q, ³*J*_{CF} = 3.9 Hz), 123.4 (q, ⁴*J*_{CF} = 1.5 Hz), 123.7 (q, ¹*J*_{CF} = 270.2 Hz), 126.2, 131.3 (q, ²*J*_{CF} = 32.5 Hz), 136.5, 152.7, 170.5.

HRMS (ESI) calc'd for C₁₇H₁₉F₃N₃O₃ *m/z* 370.1379, found *m/z* 370.1378.

(±)-4-Methoxy-6-oxo-5,8,9,10,11,11a-hexahydro-6*H*-pyrido[1,2*c*]quinazolin-10-yl acetate (9)



Prepared following the general procedure, starting from aldehyde **1g** (40 mg, 191 μ mol) and amine **2a** (21 mg, 295 μ mol), the title compound was obtained after silica gel chromatography (60% EtOAc in *n*-pentane) as a white solid (38 mg, 130 μ mol, 68%, 97/3 *cis/trans* ratio). A single crystal was prepared for X-ray diffraction studies by recrystallization from THF/pentane. CCDC 1519982 contains the supplementary crystallographic data for this

paper. The data can be obtained free of charge from The Cambridge Crystallographic Data Centre via <u>www.ccdc.cam.ac.uk/structures</u>.

¹H NMR (400 MHz; CDCl₃) δ 1.57–1.76 (m, 2H), 1.98–2.04 (m, 1H), 2.04 (s, 3H), 2.22–2.32 (m, 1H), 2.71 (ddd, J = 13.8, 12.9, 2.6 Hz, 1H), 3.85 (s, 3H), 4.55 (dd, J = 12.0, 2.5 Hz, 1H), 4.68 (ddd, J = 13.8, 4.7, 2.4 Hz, 1H), 5.00 (tt, J = 11.3, 11.3, 4.6, 4.6 Hz, 1H), 6.63–6.67 (m, 1H), 6.71–6.78 (m, 1H), 6.87–6.92 (m, 1H), 6.93–6.98 (m, 1H).

¹³C NMR (100 MHz; CDCl₃) δ 21.4, 30.6, 39.5, 41.8, 55.9, 56.7, 71.1, 109.5, 117.3, 120.2, 122.0, 125.3, 145.0, 151.9, 170.5.

HRMS (ESI) calc'd for C₁₅H₁₉N₂O₄ *m/z* 291.1345, found *m/z* 291.1359.

(±)-4-Methyl-6-oxo-5,8,9,10,11,11a-hexahydro-6*H*-pyrido[1,2-*c*]quinazolin-10-yl acetate (10)



Chemical Formula: C₁₅H₁₈N₂O₃ Exact Mass: 274.1317

Prepared following the general procedure, starting from aldehyde **1h** (40 mg, 207 μ mol) and amine **2a** (21 mg, 295 μ mol), the title compound was obtained after silica gel chromatography (50% EtOAc in *n*-pentane) as a white solid (43 mg, 155 μ mol, 75%, 97/3 *cis/trans* ratio).

¹H NMR (400 MHz; CDCl₃) δ 1.58–1.78 (m, 2H), 1.98–2.02 (m, 1H), 2.04 (s, 3H), 2.19 (s, 3H), 2.21–2.29 (m, 1H), 2.66–2.80 (m, 1H), 4.53 (dd, J = 12.0, 2.6 Hz, 1H), 4.66 (ddd, J = 13.8, 4.7, 2.4 Hz, 1H), 5.02 (ddd, J = 11.3, 6.7, 4.6 Hz, 1H), 6.76–6.92 (m, 3H), 6.98–7.06 (m, 1H).

¹³C NMR (100 MHz; CDCl₃) δ 16.6, 21.2, 30.4, 39.6, 41.7, 56.5, 70.9, 119.6, 121.2, 121.9, 123.3, 129.8, 133.7, 152.3, 170.4.

HRMS (ESI) calc'd for $C_{17}H_{22}N_3O_3 m/z$ 316.1661, found m/z 316.1675 (MeCN + H⁺ adduct).





Chemical Formula: C₁₃H₁₅N₃O₃ Exact Mass: 261.1113

Prepared following the general procedure, starting from aldehyde **1i** (40 mg, 222 μ mol) and amine **2a** (21 mg, 295 μ mol), the title compound was obtained after silica gel chromatography (50% EtOAc in *n*-pentane) as a white solid (36 mg, 137 μ mol, 62%, 92/8 *cis/trans* ratio).

¹H NMR (400 MHz; CDCl₃) δ 1.57–1.77 (m, 2H), 2.00–2.03 (m, 1H), 2.05 (s, 3H), 2.27 (ddt, J = 12.3, 4.6, 2.4, 2.4 Hz, 1H), 2.73 (ddd, J = 13.9, 13.0, 2.6 Hz, 1H), 4.56 (dd, J = 12.0, 2.7 Hz, 1H), 4.70 (ddd, J = 14.0, 4.7, 2.4 Hz, 1H), 5.01 (tt, J = 11.3, 11.3, 4.6, 4.6 Hz, 1H), 6.91 (dd, J = 7.5, 5.0 Hz, 1H), 7.37 (ddd, J = 7.5, 1.7, 0.8 Hz, 1H), 8.23 (ddd, J = 5.0, 1.7, 0.6 Hz, 1H), 8.81 (s, 1H).

¹³C NMR (100 MHz; CDCl₃) δ 21.2, 30.4, 39.4, 41.4, 55.3, 70.6, 115.4, 117.9, 133.8, 147.8, 148.9, 152.0, 170.3.

HRMS (ESI) calc'd for $C_{13}H_{16}N_3O_3 m/z$ 262.1192, found m/z 262.1210.

(±)-5-Methyl-6-oxo-5,8,9,10,11,11a-hexahydro-6*H*-pyrido[1,2-*c*]quinazolin-10-yl acetate (12)



Chemical Formula: C₁₅H₁₈N₂O₃ Exact Mass: 274.1317

Prepared following the general procedure, starting from aldehyde **1j** (40 mg, 207 μ mol) and amine **2a** (21 mg, 295 μ mol), the title compound was obtained after silica gel chromatography (30% EtOAc in *n*-pentane) as a white solid (44 mg, 160 μ mol, 77%, 98/2 *cis/trans* ratio).

¹H NMR (400 MHz; CDCl₃) δ 1.58–1.73 (m, 2H), 1.96–2.02 (m, 1H), 2.03 (s, 3H), 2.21 (ddt, J = 12.3, 4.5, 2.4, 2.4 Hz, 1H), 2.74 (ddd, J = 13.8, 12.9, 2.6 Hz, 1H), 3.33 (s, 3H), 4.46 (dd, J = 13.8, 12.9, 2.6 Hz, 1H), 3.33 (s, 3H), 4.46 (dd, J = 13.8, 12.9, 2.6 Hz, 1H), 3.34 (s, 3H), 4.46 (dd, J = 13.8, 12.9, 2.6 Hz, 1H), 3.35 (s, 3H), 4.46 (dd, J = 13.8, 12.9, 2.6 Hz, 1H), 3.55 (s, 3H), 4.46 (dd, J = 13.8, 12.9, 2.6 Hz, 1H), 3.55 (s, 3H), 4.46 (dd, J = 13.8, 12.9, 2.6 Hz, 1H), 3.55 (s, 3H), 4.46 (dd, J = 13.8, 12.9, 12.9, 12.9 (s, 3H), 4.46 (dd, J = 13.8, 12.9, 12.

ESI

= 12.0, 2.6 Hz, 1H), 4.64 (ddd, J = 13.8, 4.6, 2.4 Hz, 1H), 5.02 (ddd, J = 11.4, 6.7, 4.7 Hz, 1H), 6.83 (dd, J = 8.2, 1.0 Hz, 1H), 6.98 (td, J = 7.4, 7.4, 1.1 Hz, 1H), 7.05 (ddt, J = 7.5, 1.7, 0.6, 0.6 Hz, 1H), 7.22–7.32 (m, 1H).

¹³C NMR (100 MHz; CDCl₃) δ 21.2, 30.0, 30.2, 39.2, 43.1, 55.8, 71.0, 112.9, 121.7, 122.0, 125.5, 128.5, 138.1, 153.3, 170.3.

HRMS (ESI) calc'd for $C_{15}H_{19}N_2O_3 m/z$ 275.1396, found m/z 275.1400.

(±)-5-Allyl-6-oxo-5,8,9,10,11,11a-hexahydro-6*H*-pyrido[1,2-*c*]quinazolin-10-yl acetate (13)



Chemical Formula: C₁₇H₂₀N₂O₃ Exact Mass: 300.1474

Prepared following the general procedure, starting from aldehyde **1k** (40 mg, 182 μ mol) and amine **2a** (21 mg, 295 μ mol), the title compound was obtained after silica gel chromatography (32% EtOAc in *n*-pentane) as a white solid (45 mg, 150 μ mol, 82%, 93/7 *cis/trans* ratio).

¹H NMR (400 MHz; CDCl₃) δ 1.58–1.75 (m, 2H), 1.96–2.00 (m, 1H), 2.03 (s, 3H), 2.18–2.29 (m, 1H), 2.74 (ddd, J = 13.8, 13.0, 2.6 Hz, 1H), 4.35–4.51 (m, 2H), 4.54–4.74 (m, 2H), 5.02 (ddd, J = 11.4, 6.7, 4.7 Hz, 1H), 5.13–5.22 (m, 2H), 5.8–5.97 (m, 1H), 6.75–6.84 (m, 1H), 6.93–7.02 (m, 1H), 7.03–7.09 (m, 1H), 7.17–7.24 (m, 1H).

¹³C NMR (100 MHz; CDCl₃) δ 21.3, 30.3, 39.5, 43.2, 45.3, 56.0, 71.1, 113.9, 116.2, 121.8, 122.1, 125.7, 128.5, 133.1, 137.3, 153.0, 170.5.

HRMS (ESI) calc'd for C₁₇H₂₁N₂O₃ *m/z* 301.1552, found *m/z* 301.1549.

(±)-5-Benzyl-6-oxo-5,8,9,10,11,11a-hexahydro-6*H*-pyrido[1,2-*c*]quinazolin-10-yl acetate (14)



Exact Mass: 350.1630

Prepared following the general procedure, starting from aldehyde **1l** (40 mg, 182 μ mol) and amine **2a** (21 mg, 295 μ mol), the title compound was obtained after silica gel chromatography (35% EtOAc in *n*-pentane) as a white liquid (43 mg, 122 μ mol, 82%, 93/7 *cis/trans* ratio).

¹H NMR (400 MHz; CDCl₃) δ 1.64–1.81 (m, 2H), 2.00–2.04 (m, 1H), 2.06 (s, 3H), 2.23–2.32 (m, 1H), 2.65 – 3.38 (m, 1H), 4.54 (dd, *J* = 12.0, 2.6 Hz, 1H), 4.71 (ddd, *J* = 13.8, 4.6, 2.4 Hz, 1H), 4.99–5.14 (m, 2H), 5.17–5.28 (m, 1H), 6.70 (dd, *J* = 8.2, 1.0 Hz, 1H), 6.94 (td, *J* = 7.5, 7.5, 1.0 Hz, 1H), 7.02–7.14 (m, 2H), 7.16–7.28 (m, 3H), 7.27–7.38 (m, 2H).

¹³C NMR (100 MHz; CDCl₃) δ 21.7, 30.8, 40.1, 43.7, 47.0, 56.5, 71.5, 114.5, 122.1, 122.6, 126.1, 126.7, 127.4, 128.9, 129.1, 137.6, 138.0, 153.8, 170.8.

HRMS (ESI) calc'd for C₂₁H₂₃N₂O₃ *m/z* 351.1709, found *m/z* 351.1700.

(±)-Ethyl-2-(10-acetoxy-6-oxo-9,10,11,11a-tetrahydro-6*H*-pyrido[1,2*c*]quinazolin-5(8*H*)-yl)acetate (15)



Exact Mass: 346.1529

Prepared following the general procedure, starting from aldehyde **1m** (40 mg, 150 μ mol) and amine **2a** (21 mg, 295 μ mol), the title compound was obtained after silica gel chromatography (35% EtOAc in *n*-pentane) as a yellow liquid (38 mg, 109 μ mol, 72%, 96/4 *cis/trans* ratio).

ESI

¹H NMR (400 MHz; CDCl₃) δ 1.26 (t, *J* = 7.1, 7.1 Hz, 3H), 1.60–1.81 (m, 2H), 1.96–2.02 (m, 1H), 2.03 (s, 3H), 2.23 (ddt, *J* = 12.4, 4.5, 2.2, 2.2 Hz, 1H), 2.77 (ddd, *J* = 13.8, 13.0, 2.6 Hz, 1H), 4.14–4.28 (m, 2H), 4.49 (dd, *J* = 12.0, 2.6 Hz, 1H), 4.57–4.68 (m, 1H), 4.59–4.76 (m, 2H), 5.03 (ddd, *J* = 11.3, 6.7, 4.7 Hz, 1H), 6.61 (dd, *J* = 8.2, 1.0 Hz, 1H), 6.99 (td, *J* = 7.5, 7.4, 1.0 Hz, 1H), 7.07 (dd, *J* = 7.6, 1.6 Hz, 1H), 7.21 (ddd, *J* = 8.5, 7.3, 1.6 Hz, 1H).

NMR (100 MHz; CDCl₃) δ 14.2, 21.2, 30.2, 39.3, 43.2, 44.4, 56.0, 61.4, 70.9, 112.6, 121.8, 122.4, 125.9, 128.6, 137.0, 152.9, 169.2, 170.4.

HRMS (ESI) calc'd for C₁₈H₂₃N₂O₅ *m/z* 347.1607, found *m/z* 347.1606.

(±)-6-Oxo-8-phenyl-5,8,9,10,11,11a-hexahydro-6*H*-pyrido[1,2-*c*]quinazolin-10-yl acetate (16)



Chemical Formula: C₂₀H₂₀N₂O₃ Exact Mass: 336.1474

Prepared following the general procedure, starting from aldehyde **1a** (40 mg, 150 μ mol) and amine **2b** (150 mg, 1 mmol, prepared following the literature procedure^[3]), the title compound was obtained after silica gel chromatography (25% EtOAc in *n*-pentane) as a colorless liquid (40 mg, 119 μ mol, 55%, 98/2 *cis/trans* ratio).

¹H NMR (400 MHz; CDCl₃) δ 1.85 (td, J = 12.2, 12.2, 11.2 Hz, 1H), 1.94–2.05 (m, 1H), 2.07 (s, 3H), 2.14 (ddt, J = 12.4, 4.8, 2.3, 2.3 Hz, 1H), 2.83 (ddt, J = 13.4, 4.2, 2.0, 2.0 Hz, 1H), 4.47 (dd, J = 12.2, 2.6 Hz, 1H), 5.13–5.26 (m, 1H), 6.20 (d, J = 5.4 Hz, 1H), 6.68–6.79 (m, 1H), 6.91 (dd, J = 4.2, 0.8 Hz, 2H), 7.09–7.22 (m, 1H), 7.26 – 7.33 (m, 1H), 7.38 (dd, J = 8.5, 6.9 Hz, 2H), 7.47 (dt, J = 8.3, 1.2, 1.2 Hz, 2H), 8.18 (s, 1H).

¹³C NMR (100 MHz; CDCl₃) δ 21.3, 31.3, 40.0, 51.7, 52.1, 67.9, 113.9, 119.8, 122.2, 125.9, 126.7, 127.2, 128.5, 129.0, 135.4, 137.7, 153.4, 170.5.

HRMS (ESI) calc'd for C₂₀H₂₁N₂O₃ *m/z* 337.1552, found *m/z* 337.1559.

(±)-10-Hydroxy-5,8,9,10,11,11a-hexahydro-6*H*-pyrido[1,2-*c*]quinazolin-6one (17)



To a stirred solution of **3a** (30 mg, 115 μ mol) in methanol (1 mL) at ambient temperature was added K₂CO₃ (34 mg, 246 μ mol). The resulting solution was stirred for 17 h, after which it was partitioned between brine (10 mL) and EtOAc (10 mL). The aqueous phase was extracted into EtOAc (2x20 mL), and the combined organics were dried over MgSO₄ and concentrated in vacuo. Silica gel chromatography (6% MeOH in DCM) provided the title product as a white solid (22 mg, 100 μ mol, 88%). This transformation can also be carried out using NaOH, resulting in a slightly altered diastereomeric *cis/trans* ratio (87:13 vs. 89:11 using K₂CO₃).

¹H NMR (400 MHz; CDCl₃) δ 1.23–1.61 (m, 2H), 1.87–2.03 (m, 1H), 2.12 (ddd, J = 12.4, 4.5, 2.3 Hz, 1H), 2.70 (td, J = 13.4, 13.3, 2.6 Hz, 1H), 3.85 (tt, J = 11.0, 11.0, 4.5, 4.5 Hz, 1H), 4.45 (ddd, J = 13.7, 4.5, 2.4 Hz, 1H), 4.52 (dd, J = 11.9, 2.5 Hz, 1H), 6.72 (dd, J = 8.0, 1.1 Hz, 1H), 6.92 (td, J = 7.5, 7.5, 1.2 Hz, 1H), 7.06–7.16 (m, 2H).

¹³C NMR (100 MHz; CDCl₃) δ 33.7, 41.5, 43.0, 56.5, 68.1, 113.4, 120.6, 121.9, 125.2, 127.9, 135.6, 153.5.

HRMS (ESI) calc'd for C₁₂H₁₅N₂O₂ *m/z* 219.1134, found *m/z* 219.1132.

(±)-8,9,11,11a-Tetrahydro-6*H*-pyrido[1,2-*c*]quinazoline-6,10(5*H*)-dione (18)



Chemical Formula: $C_{12}H_{12}N_2O_2$ Exact Mass: 216.0899

To a stirred suspension of **17** (50 mg, 229 μ mol) in DCM (5 mL) at ambient temperature was added DMP (97 mg, 229 μ mol). The resulting mixture was stirred at ambient temperature overnight, after which sat. NaHCO₃ (10 mL) and Na₂S₂O₃ (26 mg) was added. The resulting aqueous phase was extracted into diethyl ether (2x40 mL), after which the combined organics were dried over Na₂SO₄ and concentrated in vacuo. The residue was purified by silica gel chromatography (30% EtOAc in hexanes) to yield the title compound as a white solid (35 mg, 164 μ mol, 72%). Spectral data were in agreement with literature values. ^[2]

(±)-5-Ethyl-6-oxo-5,8,9,10,11,11a-hexahydro-6*H*-pyrido[1,2-*c*]quinazolin-10-yl acetate (19)



Chemical Formula: C₁₆H₂₀N₂O₃ Exact Mass: 288.1474

To a stirred solution of **3a** (30 mg, 115 μ mol) in DMF (1 mL) at ambient temperature was added NaH (5 mg, 60% dispersion in paraffin) and EtI (20 mg, 128 μ mol). The resulting mixture was stirred for 40 min, after which it was partitioned between brine (10 mL) and EtOAc (10 mL). The aqueous phase was extracted into EtOAc (2x20 mL), and the combined organics were dried over MgSO₄ and concentrated in vacuo. Silica gel chromatography (30% EtOAc in *n*-pentane) provided the title product as a yellow solid (25 mg, 87 μ mol, 75%, 94/6 *cis/trans* ratio).

¹H NMR (400 MHz; CDCl₃) δ 1.17 (t, J = 7.1 Hz, 3H), 1.42–1.68 (m, 2H), 1.91 (ddd, J = 12.7, 4.8, 2.3 Hz, 1H), 1.96 (s, 3H), 2.12 (ddt, J = 12.4, 4.6, 2.3, 2.3 Hz, 1H), 2.65 (ddd, J = 13.8, 12.9, 2.6 Hz, 1H), 3.80 (dq, J = 14.5, 7.1, 7.1, 7.1 Hz, 1H), 3.94 (dd, J = 14.5, 7.2 Hz, 1H), 4.37 (dd, J = 12.0, 2.6 Hz, 1H), 4.56 (ddd, J = 13.8, 4.6, 2.4 Hz, 1H), 4.94 (tt, J = 11.3, 11.3, 4.7, 4.7 Hz, 1H), 6.78 (dd, J = 8.3, 1.0 Hz, 1H), 6.89 (td, J = 7.5, 7.4, 1.1 Hz, 1H), 6.98 (dd, J = 7.5, 1.5 Hz, 1H), 7.14–7.18 (m, 1H).

¹³C NMR (100 MHz; CDCl₃) δ 12.7, 21.3, 30.2, 37.7, 39.2, 43.0, 55.9, 71.1, 112.9, 121.8, 121.8, 125.8, 128.5, 136.9, 152.8, 170.4.

HRMS (ESI) calc'd for $C_{14}H_{16}N_3O_2 m/z$ 258.1243, found m/z 258.1249 (MeCN + H⁺ adduct).

NOE experiments for the determination of relative stereochemistry of compounds 3a, 10 and 16

The relative stereochemistry of aza-Prins compounds were determined by NOESY, DPGSE-1D-NOESY, COSY, TOCSY and X-ray diffraction studies (for compound **10**). For all compounds, a *cis* relationship exists between the benzylic hydrogen (H_a) and the hydrogen adjacent to the acetyl group (H_c). The introduction of a benzylic phenyl substituent did not have any effect on this relationship. Typically, NOE mixing times of 500–800 ms were used for selective irradiation experiments.



Literature references

- [1] M. Y. Stevens, K. Wieckowski, P. Wu, R. T. Sawant, L. R. Odell, *Organic & biomolecular chemistry* **2015**, *13*, 2044–2054.
- [2] R. T. Sawant, M. Y. Stevens, L. R. Odell, European Journal of Organic Chemistry

S17

2015, *2015*, 7743–7755.

[3] S. Pramanik, R. R. Reddy, P. Ghorai, *Journal of Organic Chemistry* **2015**, *80*, 3656–3663.

¹H and ¹³C NMR spectra





S20

ESI

































